CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors

Am J Hematol. 2020 Apr;95(4):E95-E98. doi: 10.1002/ajh.25730. Epub 2020 Jan 23.
No abstract available

MeSH terms

  • Aged
  • Aged, 80 and over
  • Clinical Trials as Topic / statistics & numerical data
  • Female
  • Follow-Up Studies
  • Humans
  • Kaplan-Meier Estimate
  • Logistic Models
  • Male
  • Middle Aged
  • Mutation*
  • Myeloid Differentiation Factor 88 / genetics
  • Prognosis
  • Progression-Free Survival
  • Proportional Hazards Models
  • Prospective Studies
  • Proteasome Inhibitors / therapeutic use*
  • Receptors, CXCR4 / genetics*
  • Treatment Outcome
  • Waldenstrom Macroglobulinemia / drug therapy
  • Waldenstrom Macroglobulinemia / genetics*
  • Waldenstrom Macroglobulinemia / mortality
  • beta 2-Microglobulin / analysis

Substances

  • CXCR4 protein, human
  • MYD88 protein, human
  • Myeloid Differentiation Factor 88
  • Proteasome Inhibitors
  • Receptors, CXCR4
  • beta 2-Microglobulin